Calcium gluconate, 100mg/ml 5ml ampoules, 10pcs

Product description

dietary supplements (dietary supplement). It is not a medicinal product.

Composition

Per 1 ml:

Active ingredient: calcium gluconate – 100.0 mg.

Auxiliary substances:

succinic acid-5.0 mg, sodium hydroxide solution of 1 M-up to pH 6.0-7.5, water for injection – up to 1.0 ml

Pharmacological action

Pharmacotherapy group: Calcium-phosphorus metabolism regulators:  

A. 12. A. A. 03 Calcium Gluconate

A. 12. A. A Calcium Preparations

Pharmacodynamics :

The calcium supplement makes up for the lack of calcium ions necessary for the transmission of nerve impulses, contraction of skeletal and smooth muscles, myocardial activity, bone formation, and blood clotting.

Pharmacokinetics:

After parenteral use with blood flow, it is evenly distributed in all tissues and organs. In the blood plasma, about 45% of calcium ions are in a complex with proteins. Passes through the placental barrier, enters breast milk. It is mainly excreted from the body by the kidneys.

Indications

-Diseases accompanied by hypocalcemia, increased permeability of cell membranes, impaired conduction of nerve impulses in muscle tissue.

– Hypoparathyroidism (latent tetany, osteoporosis), vitamin D metabolism disorders: rickets (spasmophilia, osteomalacia), hyperphosphatemia in patients with chronic renal failure.

– Increased need for calcium ions (pregnancy, breast-feeding period, period of increased growth of the body), insufficient content of calcium ions in food, violation of its metabolism (in the postmenopausal period).

– Increased excretion of calcium ions (prolonged bed rest, chronic diarrhea, secondary hypocalcemia against the background of long-term use of diuretics and antiepileptic drugs, glucocorticosteroids).

– Bleeding of various etiologies.

– Allergic diseases (serum sickness, urticaria, febrile syndrome, pruritus, itchy dermatosis(s), reactions to medication and food intake, angioedema); bronchial asthma, dystrophic alimentary edema, pulmonary tuberculosis, rickets, osteomalacia, lead colic; eclampsia.

– Hyperkalemic form of paroxysmal myoplegia.

Use during pregnancy and lactation

It can be used during pregnancy and lactation according to indications and under strict control of serum calcium concentration, since hypercalcemia negatively affects the fetus and child. When taking calcium supplements during breastfeeding, it may enter breast milk.

Contraindications

Hypersensitivity to the components of the drug, hypercalcemia (calcium concentration should not exceed 12 mg% or 6 mEq/L), hypercalciuria, nephrolithiasis (calcium), sarcoidosis, simultaneous use of cardiac glycosides (risk of arrhythmia). With caution: Dehydration, electrolyte disturbances (risk of hypercalcemia), diarrhea, malabsorption syndrome, calcium nephrourolithiasis (in the anamnesis), moderate chronic renal failure, chronic heart failure, advanced atherosclerosis, hypercoagulability, for intravenous use-children’s age (risk of necrosis).

Side effects

When administered intramuscularly or intravenously, nausea, vomiting, diarrhea, and bradycardia may occur. When administered intravenously, there may be a burning sensation in the oral cavity, a feeling of heat, with rapid intravenous use-a decrease in blood pressure, arrhythmia, fainting, cardiac arrest.

When administered intramuscularly, necrosis may form at the injection site.

Interaction

Pharmacologically incompatible with ethanol, carbonates, salicylates, and sulfates (forms insoluble or hard-to-dissolve calcium salts). Forms insoluble complexes with tetracycline antibiotics (reduces the antibacterial effect).

Reduces the effect of “slow” calcium channel blockers (intravenous use of calcium gluconate before or after verapamil reduces its hypotensive effect).

When used concomitantly with quinidine, it is possible to slow down intraventricular conduction and increase the toxicity of quinidine.

During treatment with cardiac glycosides, parenteral use of calcium gluconate is not recommended (it is possible to increase the cardiotoxic effect of cardiac glycosides).

When combined with thiazide diuretics, it may increase hypercalcemia. Reduces the effect of calcitonin in hypercalcemia. Reduces the bioavailability of phenytoin.

How to take, course of use and dosage

During treatment, it is necessary to monitor the concentration of calcium in the blood serum.

The drug is administered deep intramuscularly, or intravenously slowly (for 2-3 minutes), or dropwise, to exclude the possibility of local irritation or necrosis if the drug enters the perivascular tissue.

Due to the risk of local irritation, intramuscular injections should only be performed if intravenous injection is not possible.

Intramuscular injections should be made deep enough into the muscle, preferably in the gluteal region.

Adults: deep intramuscular injection, slow intravenous injection (for 2-3 minutes) or drip 5-10 ml of a 10% solution daily, every other day or after 2 days (depending on the nature of the disease and the clinical condition of the patient). Subsequent doses are determined in accordance with the concentration of calcium in the blood serum.

Children under 18 years of age:  the dose and method of use depend on the degree of hypocalcemia, the nature and severity of symptoms.

Children, depending on their age, the drug is administered in the following doses: up to 6 months-0.1-1 ml; 7-12 months-1-1.5 ml; 1-3 years-1.5-2 ml; 4-6 years – 2-2.5 ml; 7-14 years – 3-5 ml; older than 14 years – doses as for adults. The drug is administered every 2-3 days.

Children are not recommended to administer the drug intramuscularly due to the possible development of necrosis.

Only slow intravenous injection or intravenous infusion after dilution is recommended, in order to achieve sufficiently low rates of use and to avoid the possibility of local irritation or necrosis if the drug accidentally enters the perivascular tissue.

For intravenous infusion, the drug is diluted in a ratio of 1: 10 to a concentration of 10 mg / ml with the following infusion solutions: 0.9% sodium chloride solution or 5% glucose solution. The rate of intravenous use should not exceed 50 mg of calcium gluconate per minute.

The solution is warmed to body temperature before use. The calcium gluconate injection syringe should not contain ethanol residues (to avoid precipitation of calcium gluconate). When administered intramuscularly or intravenously, nausea, vomiting, diarrhea, and bradycardia may occur. When administered intravenously, there may be a burning sensation in the oral cavity, a feeling of heat, with rapid intravenous use-a decrease in blood pressure, arrhythmia, fainting, cardiac arrest.

When administered intramuscularly, necrosis may form at the injection site.

Overdose

Development of hypercalcemia (symptoms: drowsiness, weakness, anorexia, abdominal pain, vomiting, nausea, constipation, polydipsia, polyuria, fatigue, irritability, depression, dehydration, possible cardiac arrhythmia, myalgia, arthralgia, arterial hypertension). Severe hypercalcemia (calcium greater than 3.4 mmol/L) is life-threatening and requires immediate infusion therapy. Treatment: withdrawal of the drug; in severe cases – parenterally calcitonin at a dose of 5-10 IU / kg of body weight per day (when diluted in 500 ml of sterile 0.9% saline sodium chloride solution), intravenously drip for 6 hours. Intravenous-jet slow use 2-4 times a day is possible.

Special instructions

The drug is heated to body temperature before use.

With intravenous use, a feeling of heat may occur throughout the body, which quickly passes.

During treatment, it is necessary to carefully monitor the concentration of calcium in the blood serum.

Due to the risk of local irritation, intramuscular injections should only be performed if intravenous injection is not possible.

Intramuscular injections should be performed deep into the muscle, preferably in the gluteal region. For obese patients, a longer needle should be selected for safe insertion into muscle rather than adipose tissue. If repeated injections are necessary, the injection site should be changed each time.

With intravenous use of calcium gluconate, in exceptional cases, patients receiving cardiac glycosides should be monitored for cardiac activity and conditions should be provided for emergency treatment of cardiac complications, such as severe arrhythmias.

Calcium salts should be used with caution and only after careful determination of indications in patients with nephrocalcinosis, heart disease, and elderly patients.

Impaired renal function may be associated with hypercalcemia and secondary hyperparathyroidism. Therefore, in patients with impaired renal function, parenteral use of calcium should be prescribed only after careful determination of the indications, and it is necessary to monitor the calcium phosphate balance.

In patients with mild hypercalciuria, reduced glomerular filtration rate, or a history of nephrourolithiasis, treatment should be carried out under the control of the concentration of calcium ions in the urine.

To reduce the risk of developing nephrourolithiasis, it is recommended to drink plenty of water.

Influence on the ability to drive vehicles and fur.:The drug does not affect the concentration of attention and the speed of psychomotor reactions when driving a car and engaging in potentially dangerous activities.

Storage conditions

In a dark place, at a temperature of 20 °C to 30 °C. Do not freeze it. Keep out of reach of children.

Shelf

life is 2 years. Do not use an expired product.

Active ingredient

Calcium Gluconate

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection